We are live on ! Find out more
BAMS

Bellevue Asset Management (Switzerland) Portfolio holdings

AUM $656M
1-Year Est. Return 11.45%
This Fund
S&P 500
This Quarter Est. Return
-14.54%
1 Year Est. Return
+11.45%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$613M
AUM Growth
-$108M
Cap. Flow
+$11.4M
Cap. Flow %
1.86%
Top 10 Hldgs %
30.19%
Holding
150
New
11
Increased
47
Reduced
31
Closed
17

Top Buys

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$5.95M
2
LRMR icon
Larimar Therapeutics
LRMR
+$3.76M
3
AMGN icon
Amgen
AMGN
+$3.65M
4
INSY
Insys Therapeutics, Inc.
INSY
+$3.31M
5
HALO icon
Halozyme
HALO
+$3.1M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$6.46M
2
CAH icon
Cardinal Health
CAH
+$3.59M
3
KITE
Kite Pharma, Inc.
KITE
+$3.49M
4
MDVN
MEDIVATION, INC.
MDVN
+$3.47M
5
ALKS icon
Alkermes
ALKS
+$3.33M

Sector Composition

Rank Sector Weight
1 Healthcare 91.86%
2 Financials 0.95%
3 Industrials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
101
United Therapeutics
UTHR
$22.7B
$1.22M 0.2%
9,300
– –
KANG
102
DELISTED
iKang Healthcare Group, Inc.
KANG
$1.11M 0.18%
75,000
+25,000
+50% +$405K
INFI
103
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.1M 0.18%
130,000
-34,000
-21% -$314K
CNC icon
104
Centene
CNC
$32.9B
$1.08M 0.18%
40,000
+10,000
+33% +$335K
LH icon
105
Labcorp
LH
$26.1B
$1.08M 0.18%
11,640
– –
MNKD icon
106
MannKind Corp
MNKD
$1.26B
$963K 0.16%
60,000
– –
ESPR
107
DELISTED
Esperion Therapeutics
ESPR
$944K 0.15%
40,000
+13,000
+48% +$816K
EXEL icon
108
Exelixis
EXEL
$13.1B
$842K 0.14%
150,000
+50,000
+50% +$272K
TMH
109
DELISTED
Team Health Holdings Inc
TMH
$810K 0.13%
+15,000
New +$937K
RMD icon
110
ResMed
RMD
$31.9B
$764K 0.12%
15,000
– –
ABUS icon
111
Arbutus Biopharma
ABUS
$907M
$761K 0.12%
125,000
– –
IBB icon
112
iShares Biotechnology ETF
IBB
$9.82B
$758K 0.12%
+7,500
New +$900K
ECYT
113
DELISTED
Endocyte, Inc. Common Stock
ECYT
$724K 0.12%
158,000
– –
AFFX
114
DELISTED
Affymetrix Inc
AFFX
$683K 0.11%
80,000
– –
PRTA icon
115
Prothena Corp
PRTA
$468M
$680K 0.11%
15,000
+2,000
+15% +$116K
IPXL
116
DELISTED
Impax Laboratories, Inc.
IPXL
$634K 0.1%
18,000
-14,600
-45% -$658K
ELGX
117
DELISTED
Endologix Inc
ELGX
$613K 0.1%
5,000
– –
JNP
118
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
$589K 0.1%
50,000
-60,000
-55% -$663K
PODD icon
119
Insulet
PODD
$9.91B
$583K 0.1%
22,500
-30,000
-57% -$910K
CSII
120
DELISTED
Cardiovascular Systems, Inc.
CSII
$475K 0.08%
30,000
+10,000
+50% +$252K
PEN icon
121
Penumbra
PEN
$12.8B
$401K 0.07%
+10,000
New +$404K
IMGN
122
DELISTED
Immunogen Inc
IMGN
$288K 0.05%
+30,000
New +$439K
DYAX
123
DELISTED
DYAX CORPORATION
DYAX
$286K 0.05%
15,000
-15,000
-50% -$358K
INVA icon
124
Innoviva
INVA
$1.49B
$251K 0.04%
35,000
– –
LFWD icon
125
ReWalk Robotics
LFWD
$21.7M
$229K 0.04%
+14
New +$276K
2 3 4
5
6

Similar funds

VFAM
Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return
MSU
Maple Securities USA Jersey City, New Jersey $672M AUM 1.03% 1-Year Est. Return
PSI
Pinnacle Summer Investments Fairfax, Virginia $678M AUM 9.5% 1-Year Est. Return
SFP
Santa Fe Partners Santa Fe, New Mexico $608M AUM 8.76% 1-Year Est. Return
MCM
Mazama Capital Management Portland, Oregon $544M AUM 9.52% 1-Year Est. Return
NMIS
Northwestern Mutual Investment Services Milwaukee, Wisconsin $525M AUM 2.45% 1-Year Est. Return
SM
Stratton Management King Of Prussia, Pennsylvania $824M AUM 1.57% 1-Year Est. Return
ZAM
Zenit Asset Management Stockholm, Sweden $450M AUM 8.32% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s Q3 2015 Portfolio in Review

As of Q3 2015, Bellevue Asset Management (Switzerland) held 150 positions worth $613M, down 15% from $721M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Asset Management (Switzerland)'s Q3 2015 filing shows 11 new, 47 increased, 31 reduced and 17 closed positions. Its largest new stake was Supernus Pharmaceuticals: 320,000 shares worth $4.49M. The largest sale was RECEPTOS INC COM STK (DE), an estimated $6.46M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 90% a quarter earlier, followed by Financials and Industrials.

  • Bellevue Asset Management (Switzerland)'s largest Q3 2015 buy was Supernus Pharmaceuticals: 320,000 shares worth $4.49M.
  • Bellevue Asset Management (Switzerland) added most to Amgen in Q3 2015, an estimated $3.65M increase.
  • Bellevue Asset Management (Switzerland)'s biggest Q3 2015 reduction was Cardinal Health, cutting an estimated $3.59M.
  • Bellevue Asset Management (Switzerland) fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $6.46M.
  • Bellevue Asset Management (Switzerland)'s ten largest holdings make up 30% of its $613M portfolio in Q3 2015.
  • Bellevue Asset Management (Switzerland) opened 11 new positions and closed 17 in Q3 2015.
  • Bellevue Asset Management (Switzerland)'s portfolio value fell 15% quarter-over-quarter to $613M.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q3 2015, filed 12 Nov 2015.